According to reports, Moderna Inc is planning to double the size of an ongoing trial testing its Covid-19 vaccines in children aged between six months to less than 12 years.
The study will now enroll an estimated 13,275 participants, nearly double the earlier target of 6,975 participants, as per the updated detail on clinical trial record site clinicaltrials.gov.
In July, Moderna said it was in discussions with the US food & drug administration to expand the study with an objective to enroll a larger safety database, which increases the likelihood of detecting occasional events.
Rival shot from Pfizer Inc and its German partner BioNTech was authorized for ages 12 to 15 years earlier this year. The company’s vaccine, which received its emergency authorization for people aged 18 and older in the United States in December, is currently under an FDA review for use in adolescents.